Significant cross reactive antibodies to influenza virus in adults and children during a period of marked antigenic drift

BMC Infectious Diseases

Volumn 14, Issue 1, 2014, Pages

  Mandelboim, Michal ^a   Bromberg, Michal ^a   Sherbany, Hilda ^a   Zucker, Inbar ^a   Yaary, Karnit ^a   Bassal, Ravit ^a   Dichtiar, Rita ^a   Cohen, Danny ^b   Shohat, Tamar ^a   Mendelson, Ella ^a,b   Green, Manfred S ^c  

^a MINISTRY OF HEALTH   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c UNIVERSITY OF HAIFA   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS ANTIBODY;

ADULT; ANTIBODY DETECTION; ANTIBODY TITER; ANTIGENICITY; ARTICLE; BLOOD BANK; CHILD; CROSS REACTION; HEMAGGLUTINATION INHIBITION TEST; HUMAN; INFLUENZA VIRUS A H3N2; ISRAEL; NONHUMAN; PHYLOGENETIC TREE; POPULATION DISTRIBUTION; SEASONAL INFLUENZA; VIRUS STRAIN; BLOOD; IMMUNOLOGY; INFANT; MIDDLE AGED; PRESCHOOL CHILD; SEASON;

ADULT; ANTIBODIES, VIRAL; CHILD, PRESCHOOL; CROSS REACTIONS; HEMAGGLUTINATION INHIBITION TESTS; HUMANS; INFANT; INFLUENZA A VIRUS, H3N2 SUBTYPE; ISRAEL; MIDDLE AGED; SEASONS;

EID: 84902748262     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-14-346     Document Type: Article

References (32)

1. Gravenstein S, Davidson HE. Current strategies for management of influenza in the elderly population. Clin Infect Dis 2002, 35(6):729-737.
2. Meltzer MI, Cox NJ, Fukuda K. The economic impact of pandemic influenza in the United States: priorities for intervention. Emerg Infect Dis 1999, 5(5):659-671.
3. Iwane MK, Edwards KM, Szilagyi PG, Walker FJ, Griffin MR, Weinberg GA, Coulen C, Poehling KA, Shone LP, Balter S, Hall CB, Erdman DD, Wooten K, Schwartz B. Population-based surveillance for hospitalizations associated with respiratory syncytial virus, influenza virus, and parainfluenza viruses among young children. Pediatrics 2004, 113(6):1758-1764.
4. Stollenwerk N, Harper RW, Sandrock CE. Bench-to-bedside review: rare and common viral infections in the intensive care unit-linking pathophysiology to clinical presentation. Crit Care 2008, 12(4):219.
5. Sandrock C, Stollenwerk N. Acute febrile respiratory illness in the ICU: reducing disease transmission. Chest 2008, 133(5):1221-1231.
6. van den Wijngaard CC, Van Asten L, Koopmans MP, Van Pelt W, Nagelkerke NJ, Wielders CC, Van Lier A, van der Hoek W, Meijer A, Donker GA, Dijkstra F, Harmsen C, van der Sande MA, Kretzschmar M. Comparing pandemic to seasonal influenza mortality: moderate impact overall but high mortality in young children. PLoS One 2012, 7(2):e31197.
7. Olson DR, Simonsen L, Edelson PJ, Morse SS. Epidemiological evidence of an early wave of the 1918 influenza pandemic in New York City. Proc Natl Acad Sci U S A 2005, 102(31):11059-11063.
8. Hardy JM, Azarowicz EN, Mannini A, Medearis DN, Cooke RE. The effect of Asian influenza on the outcome of pregnancy, Baltimore, 1957-1958. Am J Public Health Nations Health 1961, 51:1182-1188.
9. Viboud C, Grais RF, Lafont BA, Miller MA, Simonsen L. Multinational impact of the 1968 Hong Kong influenza pandemic: evidence for a smoldering pandemic. J Infect Dis 2005, 192(2):233-248.
10. Baz M, Papenburg J, Hamelin ME, Ouakki M, Skowronski DM, De Serres G, Boivin G. Seroconversion to seasonal influenza viruses after A(H1N1)pdm09 virus infection, Quebec. Canada Emerg Infect Dis 2012, 18(7):1132-1134.
11. Jagger BW, Wise HM, Kash JC, Walters KA, Wills NM, Xiao YL, Dunfee RL, Schwartzman LM, Ozinsky A, Bell GL, Dalton RM, Lo A, Efstathiou S, Atkins JF, Firth AE, Taubenberger JK, Digard P. An overlapping protein-coding region in influenza A virus segment 3 modulates the host response. Science 2012, 337(6091):199-204.
12. Rossman JS, Lamb RA. Influenza virus assembly and budding. Virology 2011, 411(2):229-236.
13. Heckler R, Baillot A, Engelmann H, Neumeier E, Windorfer A. Cross-protection against homologous drift variants of influenza A and B after vaccination with split vaccine. Intervirology 2007, 50(1):58-62.
14. Lavenu A, Valleron AJ, Carrat F. Exploring cross-protection between influenza strains by an epidemiological model. Virus Res 2004, 103(1-2):101-105.
15. Skowronski D, De Serres G, Janjua N, Gardy J, Gilca V, Dionne M, Hamelin M, Rheaume C, Boivin G. Cross-reactive antibody to swine influenza A(H3N2) subtype virus in children and adults before and after immunisation with 2010/11 trivalent inactivated influenza vaccine in Canada, August to November 2010. Euro Surveill 2012, 17(4).
16. Mancini N, Solforosi L, Clementi N, De Marco D, Clementi M, Burioni R. A potential role for monoclonal antibodies in prophylactic and therapeutic treatment of influenza. Antiviral Res 2011, 92(1):15-26.
17. Sandbulte MR, Jimenez GS, Boon AC, Smith LR, Treanor JJ, Webby RJ. Cross-reactive neuraminidase antibodies afford partial protection against H5N1 in mice and are present in unexposed humans. PLoS Med 2007, 4(2):e59.
18. Fan J, Liang X, Horton MS, Perry HC, Citron MP, Heidecker GJ, Fu TM, Joyce J, Przysiecki CT, Keller PM, Garsky VM, Ionescu R, Rippeon Y, Shi L, Chastain MA, Condra JH, Davies ME, Liao J, Emini EA, Shiver JW. Preclinical study of influenza virus A M2 peptide conjugate vaccines in mice, ferrets, and rhesus monkeys. Vaccine 2004, 22(23-24):2993-3003.
19. Tompkins SM, Zhao ZS, Lo CY, Misplon JA, Liu T, Ye Z, Hogan RJ, Wu Z, Benton KA, Tumpey TM, Epstein SL. Matrix protein 2 vaccination and protection against influenza viruses, including subtype H5N1. Emerg Infect Dis 2007, 13(3):426-435.
20. Kendal APPMSJ. Concepts and Procedures for Laboratory-Based Influenza Surveillance 1982, Atlanta, GA: US Department of Health and Human Services, CDC.
21. Shil P, Chavan SS, Cherian SS. Antigenic variability in Neuraminidase protein of Influenza A/H3N2 vaccine strains (1968-2009). Bioinformation 2011, 7(2):76-81.
22. Bragstad K, Nielsen LP, Fomsgaard A. The evolution of human influenza A viruses from 1999 to 2006: a complete genome study. Virol J 2008, 5:40.
23. Jin H, Zhou H, Liu H, Chan W, Adhikary L, Mahmood K, Lee MS, Kemble G. Two residues in the hemagglutinin of A/Fujian/411/02-like influenza viruses are responsible for antigenic drift from A/Panama/2007/99. Virology 2005, 336(1):113-119.
24. Popova L, Smith K, West AH, Wilson PC, James JA, Thompson LF, Air GM. Immunodominance of antigenic site B over site A of hemagglutinin of recent H3N2 influenza viruses. PLoS One 2012, 7(7):e41895.
25. Westgeest KB, Russell CA, Lin X, Spronken MI, Bestebroer TM, Bahl J, Van Beek R, Skepner E, Halpin RA, De Jong JC, Rimmelzwaan GF, Osterhaus AD, Smith DJ, Wentworth DE, Fouchier RA, de Graaf M. Genomewide analysis of reassortment and evolution of human influenza A(H3N2) viruses circulating between 1968 and 2011. J Virol 2014, 88(5):2844-2857.
26. Hancock K, Veguilla V, Lu X, Zhong W, Butler EN, Sun H, Liu F, Dong L, DeVos JR, Gargiullo PM, Brammer TL, Cox NJ, Tumpey TM, Katz JM. Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. N Engl J Med 2009, 361(20):1945-1952.
27. Wang TT, Parides MK, Palese P. Seroevidence for H5N1 influenza infections in humans: meta-analysis. Science 2012, 335(6075):1463.
28. Iorio AM, Bistoni O, Galdiero M, Lepri E, Camilloni B, Russano AM, Neri M, Basileo M, Spinozzi F. Influenza viruses and cross-reactivity in healthy adults: humoral and cellular immunity induced by seasonal 2007/2008 influenza vaccination against vaccine antigens and 2009 A(H1N1) pandemic influenza virus. Vaccine 2012, 30(9):1617-1623.
29. Skowronski DM, Janjua NZ, De Serres G, Purych D, Gilca V, Scheifele DW, Dionne M, Sabaiduc S, Gardy JL, Li G, Bastien N, Petric M, Boivin G, Li Y. Cross-reactive and vaccine-induced antibody to emerging swine influenza A(H3N2)v. J Infect Dis 2012, 206(12):1852-1861.
30. Dreyfus C, Laursen NS, Kwaks T, Zuijdgeest D, Khayat R, Ekiert DC, Lee JH, Metlagel Z, Bujny MV, Jongeneelen M, van der Vlugt R, Lamrani M, Korse HJ, Geelen E, Sahin O, Sieuwerts M, Brakenhoff JP, Vogels R, Li OT, Poon LL, Peiris M, Koudstaal W, Ward AB, Wilson IA, Goudsmit J, Friesen RH. Highly conserved protective epitopes on influenza B viruses. Science 2012, 337(6100):1343-1348.
31. Moody MA, Zhang R, Walter EB, Woods CW, Ginsburg GS, McClain MT, Denny TN, Chen X, Munshaw S, Marshall DJ, Whitesides JF, Drinker MS, Amos JD, Gurley TC, Eudailey JA, Foulger A, DeRosa KR, Parks R, Meyerhoff RR, Yu JS, Kozink DM, Barefoot BE, Ramsburg EA, Khurana S, Golding H, Vandergrift NA, Alam SM, Tomaras GD, Kepler TB, Kelsoe G, et al. H3N2 influenza infection elicits more cross-reactive and less clonally expanded anti-hemagglutinin antibodies than influenza vaccination. PLoS One 2011, 6(10):e25797.
32. Min JY, Chen GL, Santos C, Lamirande EW, Matsuoka Y, Subbarao K. Classical swine H1N1 influenza viruses confer cross protection from swine-origin 2009 pandemic H1N1 influenza virus infection in mice and ferrets. Virology 2010, 408(1):128-133.